Skip to main content

Dengue Fever

Dengue is the world's fastest-spreading mosquito-borne viral infection, and it teaches one of the most important lessons in clinical medicine: the sickest moment often arrives just as the fever breaks. A patient who felt terrible on day two but is now afebrile on day five can be sliding into shock at the very hour everyone assumes they are recovering. Understanding dengue means understanding timing — knowing which day of illness a patient is on, watching for the leak of plasma out of blood vessels, and resisting the temptation to over-transfuse or over-hydrate.

This matters because dengue infects an estimated 100–400 million people every year across the tropics and subtropics, and while most cases are self-limited, a small fraction progress to life-threatening plasma leakage and shock. There is no specific antiviral. Survival depends almost entirely on recognizing the phase of illness and titrating fluids with precision — a skill any clinician working in an endemic area, or seeing a returning traveller, must master.

Learning Objectives​

  • Describe the dengue virus, its four serotypes, and the concept of antibody-dependent enhancement.
  • Explain the three clinical phases (febrile, critical, recovery) and why the critical phase coincides with defervescence.
  • Recognize the WHO warning signs and classify dengue as with or without warning signs, or severe.
  • Understand the pathophysiology of plasma leakage and how it drives hemoconcentration and shock.
  • Apply the principles of fluid management and know which interventions to avoid.
  • Interpret diagnostic tests (NS1 antigen, serology, PCR) by day of illness.

Quick Answer​

Dengue is caused by a flavivirus with four serotypes (DENV 1–4) transmitted mainly by Aedes aegypti mosquitoes. After a 4–10 day incubation, illness runs through three phases: a febrile phase (high fever, severe headache, retro-orbital pain, myalgia, rash), a critical phase around days 4–6 as the fever falls, and a recovery phase. The danger lies in the critical phase, when increased vascular permeability causes plasma to leak from the circulation, producing hemoconcentration, effusions, and potentially shock. Infection with one serotype gives lifelong immunity to that serotype but can worsen a later infection with a different serotype through antibody-dependent enhancement. There is no specific antiviral; management is supportive, centered on careful fluid replacement guided by the hematocrit and clinical status. Recognizing warning signs — abdominal pain, persistent vomiting, mucosal bleeding, lethargy, a rising hematocrit with a falling platelet count — is the key skill that saves lives.

Where It Came From​

Descriptions of a dengue-like illness appear in a Chinese medical encyclopedia from the Jin Dynasty (around 265–420 AD), which linked the "water poison" to flying insects. The disease became a recognizable global entity as the slave trade and expanding shipping in the 17th and 18th centuries carried Aedes aegypti — a mosquito that breeds in the water containers of ships and cities — around the tropical world. The name "dengue" likely derives from the Swahili phrase ka-dinga pepo, describing a cramp-like seizure caused by an evil spirit; the classic epidemic of 1779–1780 struck Asia, Africa, and North America almost simultaneously, the first evidence of how efficiently the virus could travel.

The modern understanding came in the 20th century. The viral cause and mosquito transmission were confirmed in the early 1900s, and the four serotypes were isolated during and after the Second World War, when troop movements in the Pacific fueled large outbreaks. The truly transformative insight arrived in the 1960s and 70s, when epidemics of severe dengue — then called dengue hemorrhagic fever — in Southeast Asia led Scott Halstead to propose antibody-dependent enhancement: the observation that a second infection with a different serotype carried a far higher risk of severe disease than a first infection. This explained why severe dengue clustered in children in endemic areas and reshaped how the world thinks about dengue immunity and vaccination.

The Virus, the Serotypes, and Antibody-Dependent Enhancement​

Dengue virus is a single-stranded RNA flavivirus, related to Zika, yellow fever, and West Nile viruses. Its four serotypes (DENV-1, -2, -3, -4) are distinct enough that immunity to one does not protect against the others. This is the crux of dengue immunology.

When a person recovers from their first (primary) infection, they develop lifelong protective antibodies against that serotype and a few months of broad cross-protection against the others. Once that cross-protection fades, a second (secondary) infection with a different serotype becomes not just possible but potentially more dangerous. In antibody-dependent enhancement (ADE), the leftover antibodies from the first infection bind the new serotype but fail to neutralize it. Instead, the antibody-coated virus is taken up more efficiently by immune cells bearing Fc receptors, amplifying viral replication and triggering a stronger inflammatory cascade of cytokines that increase vascular permeability. This is why severe dengue is classically a disease of secondary infection, and why the dengue vaccine story has been so cautious — a vaccine that acts like a "silent first infection" could prime a previously uninfected person for severe disease on their first natural exposure.

The Three Phases: Why Recovery Is the Dangerous Moment​

Dengue does not follow the intuitive "sickest when fever is highest" pattern. Its course has three distinct phases, and reading them correctly is the single most important clinical skill.

Febrile phase (days 1–3): Sudden high fever (often 39–40°C), severe frontal or retro-orbital headache, myalgia and arthralgia (the old name "breakbone fever" captures this), facial flushing, and often a blanching macular rash. Mild hemorrhagic signs such as petechiae or a positive tourniquet test can appear. Most patients feel awful but are not in danger yet.

Critical phase (days 4–6, around defervescence): As the temperature falls toward normal, a subset of patients develop increased capillary permeability. Plasma leaks out of the circulation into the pleural and peritoneal spaces. This is the window — typically lasting 24–48 hours — when shock develops. The paradox for families and inexperienced clinicians is that the patient's fever has broken and they seem to be improving, when in fact the most dangerous 48 hours have begun.

Recovery phase (days 7 onward): Leaked fluid is reabsorbed back into the circulation. The patient's appetite returns, and a characteristic confluent rash with small islands of normal skin ("isles of white in a sea of red") may appear with itching. The risk now flips: over-aggressive fluids given during the critical phase can cause fluid overload and pulmonary edema as the reabsorption occurs.

A Worked Clinical Vignette​

A 24-year-old returns from Thailand with three days of high fever, headache, and body aches. On day 4 her fever settles and she feels a little better, but she develops abdominal pain and vomits twice. Her platelet count has dropped from 140,000 to 60,000, and her hematocrit has risen from 38% to 47%. This combination — defervescence, warning signs (abdominal pain, vomiting), a rising hematocrit with a falling platelet count — signals the onset of plasma leakage. She needs admission and careful isotonic crystalloid fluids, not reassurance that "the fever has broken." The rising hematocrit alongside the falling platelets is the fingerprint of hemoconcentration from plasma leak.

Warning Signs and the WHO Classification​

The 2009 WHO scheme divides dengue into three groups, replacing the older, harder-to-apply "dengue hemorrhagic fever/dengue shock syndrome" grading:

  • Dengue without warning signs: fever plus two of — nausea/vomiting, rash, aches and pains, positive tourniquet test, leukopenia.
  • Dengue with warning signs: any of abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy or restlessness, liver enlargement more than 2 cm, or a rising hematocrit with a rapid fall in platelets. These patients need admission and close monitoring.
  • Severe dengue: severe plasma leakage causing shock or respiratory distress, severe bleeding, or severe organ involvement (e.g. AST/ALT above 1,000, impaired consciousness, myocarditis).

The warning signs matter because they identify, cheaply and at the bedside, the patients about to enter or already in the critical phase.

Real-World Applications​

  • Triage in endemic settings: In a busy tropical clinic, warning signs decide who goes home with paracetamol and daily review versus who is admitted. A patient on day 4–5 with any warning sign is admitted for hematocrit-guided fluids.
  • The returning traveller: Dengue is one of the most common causes of fever in travellers returning from Southeast Asia, the Caribbean, and Latin America. Any febrile returning traveller warrants a dengue workup alongside malaria — and the two can coexist.
  • Fluid management as the core intervention: Because there is no antiviral, outcomes hinge on giving just enough isotonic crystalloid (normal saline or Ringer's lactate) to maintain perfusion through the leak, then tapering as reabsorption begins. Serial hematocrit and urine output guide the rate.
  • Outbreak and vector control: Public health teams target Aedes breeding sites — discarded tires, water tanks, plant saucers — because the mosquito breeds in small collections of clean standing water near homes and bites during the day.

Common Mistakes​

Mistake 1: Treating fever resolution as recovery. Many assume that once the fever breaks the patient is improving. In dengue the opposite can be true — defervescence marks the start of the critical phase. The correction is to intensify monitoring, not relax it, on days 4–6.

Mistake 2: Giving aspirin or NSAIDs for the fever and pain. Aspirin and ibuprofen impair platelet function and irritate the gastric mucosa, increasing bleeding risk in a patient who is already thrombocytopenic. Paracetamol (acetaminophen) is the correct antipyretic; NSAIDs and aspirin are contraindicated.

Mistake 3: Transfusing platelets because the count is low. Thrombocytopenia in dengue can look alarming (counts of 20,000 or lower), but prophylactic platelet transfusion does not prevent bleeding and can cause harm. Platelets are given only for significant active bleeding, not for a number. The correction is to treat the patient's leak and bleeding, not the platelet count in isolation.

Mistake 4: Over-hydrating during the critical phase or continuing fluids into recovery. Because the leak is temporary, fluids given too fast or continued after reabsorption begins cause pulmonary edema. Fluid therapy must be titrated and tapered, not run wide open.

Comparison and Connections​

Dengue is often confused with other acute tropical febrile illnesses. The distinguishing features matter because their treatments differ sharply.

FeatureDengueMalariaChikungunyaTyphoid
PathogenFlavivirusPlasmodium parasiteAlphavirusSalmonella Typhi
Vector/routeAedes mosquito (day-biting)Anopheles mosquito (night)Aedes mosquitoFecal-oral
HallmarkPlasma leak, thrombocytopeniaCyclical fever, anemiaSevere persistent joint painStepwise fever, relative bradycardia
PlateletsLowLowUsually normalNormal or low
Specific treatmentSupportive onlyAntimalarialsSupportiveAntibiotics

Dengue's plasma leakage connects it conceptually to other causes of increased vascular permeability, and its immunology links directly to vaccine design. See also the branch overview at Infectious Diseases and, for the returning-traveller workup, Fever of Unknown Origin.

Practice Questions​

Recall​

Q: How many dengue serotypes are there, and what does infection with one confer? A: Four serotypes (DENV-1 to -4). Infection gives lifelong immunity to that serotype and brief cross-protection against the others, after which a different serotype can cause more severe disease.

Understanding​

Q: Why is the critical phase of dengue so dangerous even though the fever has resolved? A: Defervescence coincides with a surge in capillary permeability. Plasma leaks out of the vasculature, causing hemoconcentration and, if severe, hypovolemic shock — so the patient can deteriorate precisely when they appear to be recovering.

Application​

Q: A patient on day 5 has a hematocrit that rose from 40% to 50% while platelets fell from 90,000 to 45,000, with new abdominal pain. What phase are they in and what do you do? A: They are entering the critical phase with warning signs (rising hematocrit, falling platelets, abdominal pain). Admit for careful isotonic crystalloid fluid therapy with serial hematocrit and urine-output monitoring; avoid NSAIDs and prophylactic platelet transfusion.

Analysis​

Q: Explain how antibody-dependent enhancement complicates dengue vaccine development. A: A vaccine mimics a first infection. In a person never naturally infected, vaccine-induced non-neutralizing antibodies could, when the person later meets wild virus, enhance viral uptake and worsen disease — the same mechanism as a natural secondary infection. This is why some dengue vaccines are recommended only for people with confirmed prior infection.

FAQ​

Is dengue contagious from person to person? No. It spreads only through the bite of an infected Aedes mosquito (with rare exceptions like transfusion or vertical transmission). You cannot catch it directly from another person, but a mosquito that bites an infected person can then infect others.

Can you get dengue more than once? Yes — up to four times, once for each serotype. Because a second infection with a different serotype carries a higher risk of severe disease, previously infected people should be especially careful about mosquito exposure.

Why can't I take ibuprofen for the pain? NSAIDs and aspirin increase bleeding risk by impairing platelets and irritating the stomach, which is dangerous when your platelet count is already dropping. Use paracetamol instead and stay well hydrated.

How is dengue diagnosed, and does timing matter? Yes, timing is everything. The NS1 antigen test is most useful in the first 5 days. IgM antibodies become detectable from around day 4–5 onward, and IgG rises later (and early/high in secondary infection). PCR can detect viral RNA in the early febrile phase. A single test can be falsely negative depending on the day of illness.

When can I stop worrying about complications? Once you have passed the critical phase — typically after day 6–7 with a stable hematocrit, improving platelet count, and returning appetite — the risk of shock has passed. The recovery-phase rash and itching are reassuring signs.

Quick Revision​

  • Dengue = flavivirus, four serotypes (DENV 1–4), spread by day-biting Aedes aegypti.
  • Three phases: febrile (days 1–3), critical (days 4–6, at defervescence), recovery (day 7+).
  • The critical phase is dangerous because of plasma leakage → hemoconcentration → shock.
  • Warning signs: abdominal pain, persistent vomiting, mucosal bleeding, lethargy, fluid accumulation, liver enlargement, rising hematocrit with falling platelets.
  • Rising hematocrit + falling platelets = the fingerprint of plasma leak.
  • No antiviral; treat with careful isotonic crystalloid fluids, titrated and tapered.
  • Use paracetamol; avoid aspirin and NSAIDs; do not transfuse platelets for the number alone.
  • Antibody-dependent enhancement makes secondary infection with a new serotype more severe.
  • Diagnosis by day: NS1 and PCR early, IgM/IgG serology later.

Prerequisites​

Next Topics​